Design of Cytokine/antibody Fusion Proteins to Develop Novel Immunotherapeutics
Time: 5:00 pm
day: Conference Day One
Details:
- Linking interleukin-2 (IL-2) to an anti-IL-2 antibody modulates cytokine behavior for selective and effective disease targeting
- Cytokine pleiotropy allows for development of interventions against cancer, infection, and autoimmune diseases
- Structural insights guide engineering of cytokine/antibody fusion proteins to optimize assembly, stability, and therapeutic activity
